IDEAYA Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
IDYA$31.75-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(30,425) | $(144,165) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities | ||
| Depreciation and amortization | 1,979 | 1,815 |
| Net accretion of discounts on marketable securities | (8,452) | (18,317) |
| Stock-based compensation | 34,322 | 25,261 |
| Amortization of right-of-use assets | 1,417 | 1,376 |
| Changes in assets and liabilities | ||
| Prepaid expenses and other assets | (2,278) | (4,440) |
| Accounts payable | 3,555 | 5,304 |
| Accrued and other liabilities | 15,226 | 8,520 |
| Contract liabilities | 2,166 | — |
| Lease liabilities | 1,888 | (1,283) |
| Net cash provided by (used in) operating activities | 19,398 | (125,929) |
| Cash flows from investing activities | ||
| Purchases of property and equipment, net | (2,035) | (2,755) |
| Purchases of marketable securities | (371,751) | (854,268) |
| Maturities of marketable securities | 541,288 | 551,573 |
| Net cash provided by (used in) investing activities | 167,502 | (305,450) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock upon public offering, net of issuance costs | — | 274,690 |
| Proceeds from issuance of pre-funded warrants to purchase common stock, net of issuance costs | — | 9,400 |
| Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs | 24,901 | 379,944 |
| Proceeds from ESPP purchase | 820 | 781 |
| Proceeds from exercise of common stock options | 1,928 | 9,983 |
| Net cash provided by financing activities | 27,649 | 674,798 |
| Net increase in cash, cash equivalents and restricted cash | 214,549 | 243,419 |
| Cash, cash equivalents and restricted cash | ||
| Cash, cash equivalents and restricted cash, at beginning of period | 85,183 | 157,775 |
| Cash, cash equivalents and restricted cash, at end of period | $299,732 | $401,194 |
| Reconciliation of cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents | $298,927 | $400,283 |
| Restricted cash | 805 | 911 |
| Cash, cash equivalents and restricted cash | $299,732 | $401,194 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $— | $25 |
| Supplemental non-cash investing and financing activities: | ||
| Right-of-use asset obtained in exchange for a new operating lease liability | $6,186 | $17,515 |
| Purchases of property and equipment in accounts payable and accrued liabilities | 629 | 1,278 |
| Unpaid offering costs | — | 334 |
| Unpaid at-the-market offering program costs | $— | $16 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.